Showing 2 posts of 2 posts found.


FDA greenlights Nebriva’s Xenleta for community-acquired bacterial pneumonia

August 20, 2019
Manufacturing and Production, Sales and Marketing FDA, Nabriva, US, Xenleta, pharma, pneumonia

The FDA has awarded approval in the US to Nebriva Therapeutics’ Xenleta (lefamulin) for the treatment of adult patients with …


FDA refuses to review Nabriva’s injectable antibiotic for urinary tract infections

May 1, 2019
Research and Development, Sales and Marketing Contepo, Nabriva, pharma, urinary tract infections

Biopharma firm Nabriva Therapeutics has revealed that its antibiotic Contepo (fosfomycin) has been rejected for review by the FDA as …

Latest content